Radium dichloride
As of the edition of 20 October 2026, Radium dichloride is a small molecule: marketed, first approved in 2013 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Xofigo
- First approved
- 15 May 2013 (US)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Bayer; 3 holders in all
- Registered trials
- 59, 6 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue; Blood and lymph; Bones, joints and muscles; Heart and blood vessels
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 22 | 18 | 1 | 2 |
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 25 | 20 | 0 | 3 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 59 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Originator, Applicant and Lead sponsor of trials | 2012 to now |